Drugmakers, retailers must face ’maximum strength’ claim in decongestant false ad litigation in US
Nasdaq sees best day in over a month as Microsoft breathes life back into AI trade By Jonathan Stempel NEW YORK, July 30 (Reuters) - A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars of over-the-counter decongestants that didn’t work. The litigation comprised about 100 lawsuits filed after a U.S.
How this was made
The 30-second read
Why it matters
A federal appeals court revived portions of nationwide litigation, specifically claims tied to “maximum strength” labeling and brand-name drugs where labels could have been updated to reflect latest science. The case is returned to the district judge after an earlier dismissal.
Market read
This is a litigation procedural reversal that can extend timelines and increase expected legal risk for multiple OTC consumer health and retail pharmacy defendants.
What to watch
The article notes the FDA proposed removing oral phenylephrine from OTC oral cold meds in November 2024, which could reduce future product exposure even if litigation continues.
Background
Consumers alleged OTC oral phenylephrine decongestants did not work; an FDA advisory panel found in September 2023 that oral phenylephrine was no better than placebo.
Ticker impact
Procter & Gamble is named as a defendant, and the appeals court revived certain consumer claims tied to “maximum strength” decongestants.
Near-term sentiment pressure possible, but likely limited unless damages/settlement details emerge.
The ruling revives portions of nationwide litigation and specifically targets label wording and brand-drug labeling updates, which can extend liability timelines.
CVS is listed among retailers defendants, and the court revived decongestant false-ad claims over “maximum strength” labeling.
Stock impact likely modest unless the case escalates to material damages or settlement terms.
The decision is a procedural revival of claims returned to district court, which can increase expected legal costs and uncertainty.
GSK is named among defendants, and the appeals court revived decongestant litigation claims over label wording and updated-science labeling.
Modest negative bias possible; material move would require further case developments.
No GSK-specific product or damages details are provided beyond inclusion as a defendant.
Kenvue is listed as a defendant, and the appeals court revived consumer claims tied to oral phenylephrine decongestant “maximum strength” labeling.
Limited near-term impact unless plaintiffs’ claims broaden or settlement talks begin.
The article provides no Kenvue-specific claim scope or financial impact.
Costco is named among retailers in the decongestant false-ad litigation, and the appeals court revived certain claims.
Likely small market impact unless the case produces material damages or settlement disclosures.
The article does not specify Costco’s role beyond being a defendant, with no quantified exposure.
Target is included among retailer defendants, and the appeals court revived portions of consumer claims over decongestant labeling.
Modest effect expected without further case-specific financial details.
No Target-specific product or damages information is disclosed.
Walmart is listed among defendants, and the appeals court revived portions of nationwide decongestant litigation.
Small likely impact absent quantified damages or settlement terms.
Inclusion as a defendant is the only disclosed link; no financial specifics are provided.
Market effects
OTC consumer health and retail pharmacy chains face renewed litigation risk around FDA-adjacent labeling claims, potentially increasing legal-cost expectations across the category.
Primarily US litigation and US-listed defendant sentiment; no direct cross-border market mechanism described.
Limited global spillover, though multinational pharma exposure (e.g., GSK, Haleon, Bayer) can affect broader investor risk perception.
Counterpoint
Because most state-law claims were preempted and only narrower label-related claims were revived, the ultimate financial impact may be smaller than headline suggests.
Key entities
- companyProcter & Gamble
Defendant whose Vicks NyQuil Severe Cold & Flu is referenced; appeals court revived certain claims.
- companyHaleon
Defendant associated with Advil Sinus Congestion & Pain; appeals court revived certain claims.
- companyCVS
Retailer defendant; appeals court revived certain claims.
- regulatorFDA
Advisory panel finding and later proposed ingredient removal for oral phenylephrine.
- court2nd U.S. Circuit Court of Appeals
Revived portions of the litigation and limited other claims via preemption.
